Scholar Rock Holding Corp
A biopharmaceutical company in Cambridge, Massachusetts that develops antibody medicines for muscle-wasting diseases. Its lead therapy, apitegromab, targets a protein that limits muscle growth and is being tested for spinal muscular atrophy. Founded in 2012 by Harvard Medical School researchers, the company takes its name from Chinese "scholar's rocks"—eroded stones prized for sparking insight—because their rugged shapes resemble the protein structures it studies.
Granted 28.0K · Bought 2.72M · Sold 1.18M
Bought 2.20M
Sold 2.01M
Bought 2.19M
Granted 117.8K · Sold 5.4K
Granted 1.64M · Sold 88.1K
Granted 660.5K · Sold 39.4K
Granted 647.0K · Sold 27.0K
Granted 647.0K · Sold 27.2K
Granted 327.9K · Sold 52.3K
Granted 135.1K · Sold 52.2K
Granted 100.0K · Sold 48.1K
Granted 261.6K · Sold 135.6K
Granted 447.3K · Sold 499.3K
Granted 338.4K · Sold 339.0K
Granted 13.6K · Sold 13.6K
Granted 117.1K · Sold 45.4K
Granted 28.0K · Sold 3.4K
Granted 48.3K · Sold 48.7K
Granted 45.8K · Sold 6.0K
Granted 28.0K · Sold 5.4K
Granted 28.0K · Sold 6.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Akkaraju SrinivasDirector · 17 transactions | — | 12.23M | 28.0K | 2.72M | 1.18M |
| Artal Group S.A. +7 co-filers10% owner · 2 transactions | +24.3% | 11.26Mas of Oct 2023 | — | 2.20M | — |
| Debbane Raymond +2 co-filers10% owner · 1 transaction | — | 10.83M | — | — | — |
| Debbane Raymond +4 co-filers10% owner · 6 transactions | — | 9.25Mas of Dec 2024 | — | — | 2.01M |
| Samsara BioCapital GP, LLC +1 co-filer10% owner · 1 transaction | +47.6% | 6.79Mas of Oct 2023 | — | 2.19M | — |
| Nashat AmirDirector · 28 transactions | — | 6.24Mas of May 2024 | — | — | — |
| Burow KristinaDirector · 11 transactions | — | 4.81M | 117.8K | — | 5.4K |
| Hallal DavidChief Executive Officer, Director · 7 transactions | — | 1.84M | 1.64M | — | 88.1K |
| Vaishnaw AkshayPresident of R&D, Director · 8 transactions | — | 630.5K | 660.5K | — | 39.4K |
| Woods KeithChief Operating Officer · 5 transactions | — | 620.1K | 647.0K | — | 27.0K |
| Sinha VikasChief Financial Officer · 5 transactions | — | 619.9K | 647.0K | — | 27.2K |
| Backstrom Jay T.CHIEF EXECUTIVE OFFICER, Director · 5 transactions | +183.7% | 425.6Kas of Mar 2025 | 327.9K | — | 52.3K |
| Ho JunlinGENERAL COUNSEL · 12 transactions | +52.3% | 241.5K | 135.1K | — | 52.2K |
| Parlavecchio CarynCHRO · 13 transactions | +44.3% | 169.1K | 100.0K | — | 48.1K |
| Marantz Jing L.CHIEF MEDICAL OFFICER · 19 transactions | — | 126.0K | 261.6K | — | 135.6K |
| Myles Edward HCOO & CFO · 26 transactions | -45.4% | 111.3Kas of Mar 2025 | 447.3K | — | 499.3K |
| Qatanani MoCHIEF SCIENTIFIC OFFICER · 44 transactions | +369.7% | 98.6K | 338.4K | — | 339.0K |
| Moore ErinInterim PFO and PAO · 3 transactions | — | 96.2Kas of Mar 2025 | 13.6K | — | 13.6K |
| Sacco TraceyChief Commercial Officer · 12 transactions | — | 76.3Kas of Apr 2025 | 117.1K | — | 45.4K |
| Gilman MichaelDirector · 7 transactions | +65.7% | 62.1K | 28.0K | — | 3.4K |
| Flier Jeffrey S.Director · 10 transactions | — | 42.0K | 48.3K | — | 48.7K |
| Peng KatieDirector · 11 transactions | — | 39.7K | 45.8K | — | 6.0K |
| Reed JoshuaDirector · 5 transactions | — | 22.6K | 28.0K | — | 5.4K |
| Brudnick RichardDirector · 5 transactions | — | 21.9K | 28.0K | — | 6.1K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +2.48M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.